BioSpace News Archive

resTORbio announced the initiation of a randomized, double-blind, placebo-controlled trial of RTB101, an investigational orally-administered potent small molecule inhibitor of target of rapamycin complex 1, as compared to placebo for COVID-19 prophylaxis in nursing home residents.

BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the Jefferies Virtual Healthcare Conference. Presentation Details: Event: Jefferies Virtual Healthcare Conference Date: Thursda

Dr. Tina Cheng Committed to Research Innovation That Helps Patients, Family and Community Health [28-May-2020] CINCINNATI , May 28, 2020 /PRNewswire/ -- Tina L. Cheng , MD, MPH, will be the new chair of the Department of Pediatrics at the University of Cincinnati College of Medicine , the new chief medical officer at Cincinnati Children’s Hospital Medical Center

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare Conference at 2:30 p.m. EDT . The conference will be held in a virtual meeting format. Presentation details: Event: Jefferies 2020 Healthcare Conference

Protagonist Therapeutics, Inc. announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at two upcoming virtual healthcare investor conferences.

Theraly Fibrosis, a preclinical-stage biotechnology company focused on development and commercialization of drugs for various fibrotic diseases announced that the US Food and Drug Administration has granted Orphan Drug Designation to TLY012 for the treatment of systemic sclerosis.

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that the Company will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 2:30 p.m. EDT. A live webcast of the presentation will be available on the investors section of the Company’s website at www.v

BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference.

Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, announced the hiring of Róisín Armstrong, PhD. Dr. Armstrong, a seasoned drug developer, will head the development of the Company’s lead program, RLYB211.

Oral presentation to highlight clinical data for olutasidenib, an investigational agent, in IDH1 mutant gliomas, including confirmation of blood-brain barrier penetration and preliminary disease control for patients with recurrent, predominantly enhanced glioma